baculoFECTIN II转染试剂150 ul

Product Name: Rubella Virus IgG – ELISA

# of Samples: 1 x 96 Assays

Intended Use: The Rubella virus IgG-ELISA is intended for the quantitative determination of IgG class antibodies against Rubella virus in human serum or plasma (citrate).

Introduction: Rubella is an enveloped RNA virus belonging to the toga viruses. It has a spherical shape measuring about 50-70 nm in diameter. There appears to be only one antigenic type, and no cross-reactivity with alpha viruses or other members of the toga virus group has been found. Rubella viruses are pathogens of the respiratory tract and transmitted mainly by droplet infection. Rubella is a worldwide common contagious disease with mild constitutional symptoms and a generalized rush. In childhood, it is an inconsequential illness, but when it occurs during pregnancy, there is a significant risk of severe damage to the foetus.
The risk of congenital rubella depends primarily on the month of pregnancy in which infection is acquired: overall, app. 16% of infants have major defects at birth following maternal rubella in the first 3 months of pregnancy. Congenital rubella infection may lead to a syndrome with single or multiple organ involvements, known as embryopathia rubeolosa. In some cases infection is inapparent but results in consequential damages as eye defects, deafness, growth retardation, and others. Naturally acquired immunity usually is long-lasting, but reinfection is possible due to decreasing levels of circulating antibodies. For immunization a vaccine containing live virus is used.
Infection may be identified by
Detection of virus by PCR (prenatal)
Hemagglutination inhibition (HAI), Haemolysis-in-gel test (HiG)
Detection of antibodies by EIA, ELISA

Principles of the assay: The quantitative immunoenzymatic determination of IgG-class antibodies against Rubella Virus is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique.
Microtiter strip wells are precoated with Rubella Virus antigens to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample material horseradish peroxidase (HRP) labelled anti-human IgG conjugate is added. This conjugate binds to the captured Rubella-specific antibodies. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of Rubella specific IgG antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450 nm is read using an ELISA microwell plate reader.

Storage and Stability: The reagents are stable up to the expiry date stated on the label when stored at 2...8 C.

References: Reef Se., Frey Tk., Theall K., Aabernathy E., Burnett Cl., Icenogl J., McCauley Mm., Wharton M. The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention. JAMA. 2002 Jan 23-30;287(4):464-72.Mezzasoma L Bacarese-Hamilton T., Di Christina M., Rossi R. Bistoni F., Crisanti A. Antigen microarrays for serodiagnosis of infectious diseases. Clin Chem. 2002 Jan;48(1):121-30.Cooper Lz. Current lessons from 20th century serosurveillance data on rubella. Clin Infect Dis. 2001 Oct 15;33(8):1287.Signore C. Rubella. Prim. Care Update Ob Gyns. 2001 Jul;8(4):133-137.Weber B. Current developments in the laboratory diagnosis of rubella. Bull Soc Sci Med Grand Duche Luxemb. 1997;134(2):31-41.Voller,A. and D.E. Bidwell. 1975. A simple method for detection antibodies to rubella.Brit.J.Exp.Pathology 56 : 338 339